Dec 23, 2019 8:31 pm EST Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
Nov 26, 2019 7:55 am EST Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia
Nov 18, 2019 8:38 am EST Acasti Pharma Releases Preliminary New Animal Data, and Gains Insights Into CaPre’s Novel Mechanism of Action in Diabetes
Nov 13, 2019 7:55 am EST Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2020
Nov 7, 2019 8:30 am EST Acasti Pharma Announces Publication of CaPre Pharmacokinetics Study in a Leading Peer-Reviewed Journal
Oct 1, 2019 9:00 am EDT Acasti Pharma to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
Sep 30, 2019 8:35 am EDT Acasti Pharma Announces Additional Phase 3 Milestones Reached, and Remains on Track to Report Topline Results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020
Sep 9, 2019 8:30 am EDT Acasti Pharma Receives Funding from the Government of Canada to Expand Production Capacity